Pay in 4 interest-free payments of $6.94 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
This compares to a combined total of less than 500 listings removed across the previous two years.
Further extending the clinical evaluation, a Phase I trial (NCT04630860) focused on advanced-stage PD patients to assess the safety and pharmacokinetics of LY03003 via intramuscular administration
Biology and management of patients with triple-negative breast cancer
Acknowledgements This work is funded by the National Natural Science Foundation of China (81530028
US$ 25.82
US$ 26.76
US$ 23.10
US$ 29.41
US$ 28.20
US$ 21.02
US$ 26.17
US$ 22.46
US$ 21.53
US$ 24.58
US$ 26.89
